详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis.

文献详情

资源类型：

Pubmed体系：

作者：

单位： [1]Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China. [2]Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China. [3]First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. [4]First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, China. [5]Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China. [6]Second People's Hospital, Fujian University of Traditional Chinese Medicine, Fuzhou, China. [7]Tongji Hospital Affiliated to Tongji Medical School, Huazhong University of Science and Technology, Wuhan, China. [8]Department of Honghu, Hubei Province Hospital of Traditional Chinese Medicine, Honghu, China. [9]Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China. [10]Xuanwu Hospital, Capital Medical University, Beijing, China. [11]First Affiliated Hospital of the Henan University of Traditional Chinese Medicine, Zhengzhou, China. [12]Southwest Hospital, Army Medical University, Chongqing, China. [13]Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China. [14]Bethune International Peace Hospital, People's Liberation Army, Shijiazhuang, China. [15]Shanghai Guanghua Hospital of Integrated Traditional and Western Medicine, Shanghai, China. [16]Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China. [17]Henan Rheumatism Hospital, Zhengzhou, China. [18]China-Japan Friendship Hospital, Beijing, China. [19]Shenzhen Hospital, Peking University, Shenzhen, China. [20]Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China. [21]Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.

出处：

DOI：

ISSN：

摘要：

Tripterygium wilfordii Hook F (TwHF) is one of the most commonly used and effective traditional Chinese herbal medicines against rheumatoid arthritis (RA). Both Tripterygium Glycoside Tablets (TGT) and Tripterygium wilfordii Tablets (TWT) are the representative TwHF-based agents enrolled into the 2019 edition of Medicine Catalog for National Basic Medical Insurance, Injury Insurance, and Maternity Insurance. However, individual differences in TGT/TWT response across patients usually exist in the process of treating RA, implying that the clinical application of the two agents may not be standardized leading to the ineffective treatment and the risk of side effects. Growing evidence show that the bioactive constituents of TwHF may often have toxicity, the package insert of TGT and TWT may not be described in detail, and the therapeutic windows of the two agents are narrow. Thus, it is an urgent task to develop a standardized clinical practice guideline for TGT and TWT in the treatment of RA. In the current study, a group of clinical experts of traditional Chinese medicine and Western medicine in the research field of rheumatism diseases, pharmacists, and methodologists of evidence-based medicine were invited to select the clinical questions, to determine the levels of the evidence and the strength of the recommendations, and to develop the recommendations and good practice points. The guideline is formed based on the combination of clinical research evidence and expert experience (evidence-based, consensus, supplemented by experience). The clinical problems which are supported by clinical evidence may form recommendations, and the clinical problems without clinical evidence may form experts' suggestions. Both recommendations and experts' suggestions in this guideline summarized the clinical indications, usage, dosage, combined medication, and safety of TGT and TWT against RA systematically and comprehensively, which may offer a professional guidance in the context of the clinical application of the two TwHF-based agents.Copyright © 2021 Lin, Zhang, Jiang, Liu, Liu, Huang, Wu, Tu, Zhou, Chen, Li, Ding, Fang, Liu, Li, He, Chen, Lou, Tao, Wang, Jin, Liao, Li and Wang.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2019]版：

大类 | 2 区医学

小类 | 2 区药学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区药学

JCR分区：

出版当年[2018]版：

Q1 PHARMACOLOGY & PHARMACY

最新[2023]版：

Q1 PHARMACOLOGY & PHARMACY

影响因子： 最新[2023版] 4.4 最新五年平均[2021-2025] 5 出版当年[2018版] 3.845 出版当年五年平均[2014-2018] 4.469 出版前一年[2017版] 3.831 出版后一年[2019版] 4.225

第一作者：

第一作者单位： [1]Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：